Comments on: 'Four‐year data from use of the nut and soya testing protocol before treatment with isotretinoin and alitretinion': reply from authors.
- Resource Type
- Article
- Authors
- Alden, K.; Chowdhury, M. M. U.; Williams, P. E.; Kalavala, M.
- Source
- Clinical & Experimental Dermatology. Jun2021, Vol. 46 Issue 4, p733-734. 2p. 1 Graph.
- Subject
- *SOYBEAN
*ISOTRETINOIN
*MEDICAL protocols
*SOY oil
*MEDICAL personnel
- Language
- ISSN
- 0307-6938
Further prospective studies are needed, and drug challenge testing and potential skin prick testing of selected patients with isotretinoin and its constituents is the next step if no alternative treatments are suitable. We read with interest and accept some of the points made by McCarthy I et al i .1 and Ostlere and Bansal2 on our paper regarding drug challenge and skin prick testing with isotretinoin. This is also in line with European Medicines Agency (EMA) guidelines.6 The latest data in October 2020 from Roche states that its isotretinoin capsule formulated to contain 20 mg isotretinoin also contains 215.8 mg refined soya oil, 15.4 mg hydrogenated soya oil and 61.4 mg partially hydrogenated soya oil (total 292.6 mg soya bean oil).7 Hence, the average dosages of 40-60 mg of isotretinoin will contain double or triple the listed soya oil content per day. [Extracted from the article]